Kidney transplantation offers patients with end stage renal disease a path away from dialysis, but the risk of acute rejection remains a central challenge for clinicians and transplant programmes. Clarava has been developed to address this risk earlier in the transplant pathway by identifying patients who may be more likely to experience rejection before surgery takes place.
Current risk assessment before kidney transplantation relies largely on clinical indicators and antibody testing. Physicians typically evaluate factors such as donor compatibility, prior transplant history and levels of donor specific antibodies to estimate whether a patient might face a higher probability of rejection. While these measures provide useful guidance, they do not fully capture the complexity of the immune response that ultimately determines how the body reacts to a transplanted organ.
Clarava focuses on the biological signals that underpin this immune activity. The test analyses a specific RNA gene expression signature from a patient’s blood sample during the pre transplant evaluation stage. By examining patterns of gene activity associated with immune system behaviour, the platform aims to classify transplant candidates according to their likelihood of developing acute rejection after the procedure.
Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.
